George Lloyd
Equibles does not estimate personal net worth.
Get an email with a short summary when Royalty Pharma plc publishes a filing, an earnings call transcript or a press release.
Get RPRX alertsAbout George Lloyd
The proxy statement of Royalty Pharma plc reports total compensation of $1,323,000 for George Lloyd in fiscal 2025, including a base salary of $1,323,000. Disclosed compensation is on record for 3 fiscal years. Royalty Pharma plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Royalty Pharma plc includes Pablo Legorreta (CEO), Vlad Coric (CEO and Board Member), Christopher Hite (Chairman) and 7 others.
Affiliation history
-
Royalty Pharma plc (RPRX)
Proxy statement
CurrentStart not stated–present
Last confirmed April 10, 2026
-
Start not stated–2022-04-28
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Royalty Pharma plc
- Pablo Legorreta CEO
- Vlad Coric CEO, Board Member
- Christopher Hite Chairman
- David Hodgson Chairman
- Gregory Norden CFO
- Terrance Coyne CFO
- Arthur McGivern General Counsel
- Arthur R. McGivern General Counsel
- Carole Ho Board Member
- Catherine Engelbert Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Royalty Pharma plc (RPRX) | Senior Advisor; former Executive Vice President, Chief Legal Officer & Investments | $1,323,000 | $1,323,000 |
| 2024 | Royalty Pharma plc (RPRX) | Senior Advisor; former Executive Vice President, Chief Legal Officer & Investments | $1,260,000 | $1,260,000 |
| 2023 | Royalty Pharma plc (RPRX) | Senior Advisor; former Executive Vice President, Chief Legal Officer & Investments | $1,200,000 | $4,560,000 |
Recent activity
No call appearances or filed executive changes recorded yet.